Bacterial bioluminescence is very sensitive to cerulenin, a fungal antibiotic which is known to inhibit fatty acid synthesis. When Vibrio harveyi cells pretreated with cerulenin were incubated with [3H]myristic acid in vivo, acylation of the 57-kilodalton reductase subunit of the luminescence-specific fatty acid reductase complex was specifically inhibited. In contrast, in vitro acylation of both the synthetase and transferase subunits, as well as the activities of luciferase, transferase, and aldehyde dehydrogenase, were not adversely affected by cerulenin. Light emission of wild-type V. harveyi was 20-fold less sensitive to cerulenin at low concentrations (10 jig/ml) than that of the dark mutant strain M17, which requires exogenous myristic acid for luminescence because of a defective transferase subunit. The sensitivity of myristic acid-stimulated luminescence in the mutant strain M17 exceeded that of phospholipid synthesis from ['4C]acetate, whereas uptake and incorporation of exogenous ['4C]myristic acid into phospholipids was increased by cerulenin. The reductase subunit could be labeled by incubating M17 cells with [3H]tetrahydrocerulenin; this labeling was prevented by preincubation with either unlabeled cerulenin or myristic acid. Labeling of the reductase subunit with [3H]tetrahydrocerulenin was also noted in an aldehyde-stimulated mutant (A16) but not in wild-type cells or in another aldehyde-stimulated mutant (M42) in which [3H]myristoyl turnover at the reductase subunit was found to be defective. These results indicate that (i) cerulenin specifically and covalently inhibits the reductase component of aldehyde synthesis, (ii) this enzyme is partially protected from cerulenin inhibition in the wild-type strain in vivo, and (iii) two dark mutants which exhibit similar luminescence phenotypes (mutants A16 and M42) are blocked at different stages of fatty acid reduction.
Bacterial luminescence results from the luciferase-catalyzed oxidation of a long-chain aliphatic aldehyde (myristyl aldehyde) and reduced flavin mononucleotide by molecular oxygen (for a review, see reference 16) . The aldehyde substrate is synthesized by a luminescence-specific fatty acid reductase complex consisting of three subunits: an acyltransferase (T) responsible for supplying endogenous fatty acid from acyl-acyl carrier protein (ACP) (4, 8) ; a synthetase (S) which activates fatty acid to form acyl-S via an acyl-AMP intermediate (22, 25) ; and a reductase (R) which uses NADPH to reduce acyl-S (or acyl-coenzyme A [CoA] ) to produce the corresponding aldehyde (23) . The fatty acid reductase complex and luciferase are coordinately induced during the late-exponential growth phase characteristic of light emission in vivo (16) .
Cerulenin [(2S)(3R)-2,3-epoxy-4-oxo-7,10-dodecadienoyl amide] is an antibiotic produced by Cephalospori-imn aleriilens, which is known to inhibit fatty acid and sterol synthesis, fatty acylation of proteins, and other membrane-related processes (for a review, see reference 19) . Apart from its effects on fatty acid synthesis, where it has been shown to covalently and irreversibly inhibit P-ketoacyl-ACP synthetase (9, 29) , the site(s) and mechanism of cerulenin inhibition in the above processes are largely unknown. The sensitivity of bacterial bioluminescence to cerulenin was originally reported by Ulitzur and Goldberg (27) and used by these authors to develop a bioassay for this compound. Grogan (11) demonstrated that inhibition of bioluminescence by cerulenin is not caused by its primary effect on fatty acid biosynthesis and suggested that fatty acid reduction to aldehyde could be the impaired step.
This investigation was undertaken to elucidate the enzymatic step(s) at which cerulenin inhibits bioluminescence in Vibrio harveyi, a species for which a number of dark mutants have been characterized. The results clearly demonstrate that cerulenin specifically and covalently blocks the transfer, reduction, or both, of fatty acids at the level of the R subunit in vivo and that the extent of this inhibition may be a function of the fatty acyl flux through the enzyme system.
MATERIALS AND METHODS
Materials. [9,10-3H] [7, 8, 10, (150 Ci/mmol) was prepared in a similar manner from cerulenin by Du Pont Canada Ltd. (NEN Products, Lachine, Quebec, Canada) and was further purified by thin-layer chromatography before use (21) . Sodium [1-'4C] acetate (58 Ci/mol), myristic acid (60 Ci/mol), and En3Hance were also purchased from Du Pont Canada Ltd.
[3H]myristoyl-CoA (23) and [3Hlmyristoyl-ACP (8) (5) . The incorporation of labeled precursor was calculated from the percentage of total radioactivity in the phosphatidylethanolamine, phosphatidylglycerol, and cardiolipin bands and from the specific radioactivity of the added precursor.
Enzyme assays. Cell lysis and enzyme assays were carried out as described earlier (6) . Briefly, cell-free extracts for enzyme assays and in vitro fatty acid labeling studies were prepared by sonication of cell pellets (from 20 ml of culture) in 1 ml of 50 mM phosphate-10 mM P-mercaptoethanol (pH 7.0), followed by centrifugation (17,000 x g, 30 min). Luciferase activity was measured by monitoring luminescence after the injection of catalytically-reduced flavin mononucleotide into solutions containing extract and decyl aldehyde (12) . Aldehyde dehydrogenase activity was determined spectrophotometrically (7) , while transferase (acyl-ACP cleavage) activity was measured by liquid scintillation counting of the hexane-soluble radioactivity after incubation with
[3H]myristoyl-ACP (8) . Details are provided in the Table 1 footnotes. Protein was measured by using the Bio-Rad Laboratories dye-binding assay (2) , with bovine serum albumin used as a standard. 
RESULTS
Although previous investigations have examined the inhibition of luminescence by cerulenin with both the wild-type and mutant M17 strains of V. harveyi (11, 27) , the relative sensitivities of these strains to the antibiotic under conditions that do not inhibit bacterial growth have not been reported. In the experiment shown in Fig. 1 , light emission was monitored as a function of time after the addition of cerulenin at a sublethal concentration: 10 p.Lg/ml (27) . Wildtype luminescence was inhibited about fivefold over the 45-min incubation period, while the decrease in myristic acid-stimulated luminescence of the M17 mutant was much more dramatic (100-fold) over the same period (Fig. 1) . Addition of decyl aldehyde to either strain after cerulenin inhibition immediately and completely restored light emission to control levels (data not shown), consistent with previous observations that cerulenin does not adversely affect either luciferase or the overall cellular metabolism supporting bioluminescence (11, 27) . This was also shown directly by assaying the in vitro activities of luminescencerelated enzymes from cerulenin-treated cultures: no appreciable inhibition of either luciferase, aldehyde dehydrogenase, or T (acyl-ACP cleavage) was observed ( Table 1) .
The sensitivity of the M17 mutant to cerulenin raises the possibility that myristic acid uptake (which presumably must occur for the stimulation of light emission in this dark mutant) is a preferential site of inhibition. This was addressed by measuring the incorporation of radiolabeled precursors into phospholipids in parallel with luminescence as a function of cerulenin concentration in the M17 mutant (Fig. 2) . Both luminescence and [14C]acetate incorporation into total phospholipid (i.e., reflecting acetate uptake, de novo fatty acid synthesis, and phospholipid acylation) were inhibited to a similar extent at low cerulenin concentrations Fig. 1 legend) were preincubated for 45 min in the presence (+) or absence (-) of 10 p.g of cerulenin per ml. Cell-free extracts (7 to 9 mg of protein per ml) were prepared and used to measure enzyme activities as described below and in the text. The mean of duplicate determinations is shown.
h Luciferase activity was determined by using 1 ,ul of extract and 60 puM decyl aldehyde in 1 ml of 50 To determine the site(s) of aldehyde synthesis that might be directly affected by cerulenin, the effect of this agent on the acylation of luminescence-specific enzyme intermediates was examined. We have previously shown that, while fatty acid reductase activity cannot be detected in extracts of V. harveyi, the R, S, and T enzymes from this the M17 mutant, in which increased acylation of the S subunit was observed) (Fig. 3) . In vitro labeling of the R subunit is variable (30) and was not observed in this experiment. Cerulenin did produce a decrease in labeling of the T enzyme in vivo; however, this was not observed with either
[3H]myristic acid or [3H]myristoyl-CoA in vitro (Fig. 3) , nor was there any effect on the activity of this enzyme (Table 1) . This could be a secondary effect, since cerulenin also inhibited the labeling of the 20-kDa band identified as the acyl-ACP substrate of the T enzyme (7), as well as proteins in the 50-kDa range that are not luminescence specific (30) . In any case, the present data suggest that the specific effect of cerulenin on the luminescence system is via inhibition of the reductase enzyme.
The above conclusion was supported by incubating M17 cells with the radiolabeled cerulenin analog [3H]tetrahydrocerulenin, which has previously been used to detect fatty acid synthetase and related enzymes in cell extracts (21) . Despite prior purification of [3H]tetrahydrocerulenin by thinlayer chromatography, the compound was very unstable and many bands were invariably detected by SDS-PAGE and fluorography under our labeling conditions (Fig. 4) . However, only a single protein of 57 kDa (i.e., corresponding in size to the R subunit) appeared to be specifically modified by the inhibitor (Fig. 4, lane 1) , since its labeling was abolished by preincubation of cells with unlabeled cerulenin (lane 3) and was substantially reduced in the presence of myristic acid (lane 2). These results strongly indicate that the R subunit is specifically and covalently inhibited by cerulenin and suggest that myristic acid can partially protect the enzyme from this modification.
Labeling of the reductase subunit by [3H]tetrahydrocerulenin in the V. harveyi wild type and dark mutants was found to be highly strain specific (Fig. 5) . In contrast to the M17 mutant, little or no labeling of the R subunit was observed with the wild-type strain, which indicated a correlation between [3Hltetrahydrocerulenin modification and sensitivity of light emission to cerulenin (Fig. 1) involved in aldehyde synthesis. Moreover, they suggest that the A16 and M42 mutants, both defective in aldehyde synthesis from fatty acid, are blocked at different stages of the fatty acid reductase pathway.
To further explore possible differences in the enzyme defects of aldehyde-deficient V. harveyi mutants, the turnover of fatty acyl-enzyme intermediates was investigated in an in vivo pulse-chase experiment with [3H]myristic acid. The [3H]myristoyl-enzyme intermediates of the S and R subunits could be chased effectively with unlabeled fatty acid in the wild-type strain as well as in the M17 mutant (in which a lower level of steady-state acylation was observed; 30) (Fig. 6 ). This evidence for catalytic turnover was expected, since both strains exhibit the ability to reduce fatty acid to aldehyde in vivo. As noted previously (30) , neither the S nor R subunit was acylated by [3H]myristic acid in the A16 mutant, which is defective in aldehyde synthesis. In contrast, the S subunit was heavily pulse-labeled in the M42 mutant, while the reductase enzyme was acylated at a much lower level in comparison to the wild type (Fig. 6 ). Label associated with the S subunit was chased by unlabeled fatty acid, but no turnover of acyl groups on the R subunit was observed. These results confirm that the two aldehydestimulated dark mutants A16 and M42 are biochemically distinct, which further indicates that different molecular lesions of fatty acid reduction to aldehyde are involved.
DISCUSSION
Cerulenin is known to inhibit a variety of membranerelated processes, such as fatty acid, sterol, and polyketide synthesis (19) , as well as protein acylation (14, 26) and antigen processing (10) . In most cases, the primary site of cerulenin action in these processes has not been established. The exception is fatty acid synthesis, where covalent inhibition of the rate-limiting condensing enzyme, f-ketoacyl-ACP synthetase, has been demonstrated (9, 29 (Fig. 4) ; this is not too surprising given the high background of labeling in our system and the fact that the reductase enzyme is more abundant than most other enzymes in induced luminescent bacteria (31) . In agreement with our conclusions, recent studies have shown that cerulenin reacts directly with the purified R subunit from Photobacterium phosphoreum (L. Wall, personal communication).
The observation that luminescence is at least as sensitive to cerulenin as fatty acid synthesis in the M17 mutant raises the possibility that the R enzyme and P-ketoacyl-ACP synthetase share some common mechanistic or structural (or both) features at the active site. Previous studies have indeed indicated that reductase activity involves acylation and deacylation at a site on the enzyme which is sensitive to thiol reagents (32) . However, caution must be exercised in the comparison of cerulenin sensitivities in vivo; the present data show that the apparent sensitivity of R to cerulenin may be a function of the level of substrate protection with fatty acid under various conditions. For example, the reduced labeling of the wild-type enzyme with [3H]tetrahydrocerulenin (Fig. 5) can also be obtained with M17 cells preincubated with myristic acid (Fig. 4) . Thus, the flux of acyl groups through the active site (and perhaps also the structural integrity of the mutant enzyme complex) must be considered before more specific conclusions can be drawn from an in vivo comparison.
On the basis of the present data, we propose that the aldehyde-stimulable A16 and M42 mutants of V. harveyi are blocked at different steps in the fatty acid reduction pathway. The lack of acylation of either the S or R subunit with
[3H]myristic acid in the A16 mutant (Fig. 6) , coupled with the sensitivity of R to labeling with [3H]tetrahydrocerulenin (Fig. 5) , suggests that the defect in this strain involves the activation of fatty acid to acyl-AMP or the subsequent acylation of the synthetase subunit at a Cys residue in the active site (24) . On the other hand, the lack of acyl turnover at the R subunit in the M42 mutant (Fig. 6 ) and the further indication that the acylation site in this enzyme may be blocked to the action of cerulenin in vivo (Fig. 5) are consistent with a defect at this site, perhaps in the reduction of acyl-R by NADPH (i.e., in the off-loading of acyl groups from this site). Since cerulenin specifically decreases acylation of the R subunit with [3Hjmyristic acid (and under certain circumstances increases acylation of the S subunit [ Fig. 3]) , it would appear to act by preventing the transfer of fatty acyl groups from S to R. The above interpretations are summarized in the model shown in Fig. 7 ; this model is based on the enzymatic steps elucidated using P. phosphoreum (24) and assumes equivalent reactions in V. harveyi. Further work is required to test and extend these hypotheses, perhaps by studying the purified enzymes from P. phosphoreum or by cloning and sequencing the mutant enzymes from V. harveyi, as has been recently achieved for the T subunit from the M17 mutant (17) .
